To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab)
and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed
study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and
Cyclosporine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rockefeller University
Collaborator:
Facet Biotech
Treatments:
Cyclosporine Cyclosporins Daclizumab Immunoglobulin G